Table 6.

Summary of the pharmacokinetic parameters of pyragrel in a 3×3 crossover study (60, 120, or 240 mg) in 12 healthy volunteers (Part IV).

Parameters	Unit	Pyragrel (n=12)a
		60 mg	120 mg	240 mg
t1/2	h	4.28 ± 1.84	4.82 ± 1.63	5.06 ± 1.58
Tmax	h	2.75 ± 0.45	2.58 ± 0.51	2.92 ± 0.29
Cmax	µg·L-1	641.2 ± 107.8	1505.6 ±178.7	3165.7 ± 426.4
AUClast	h*µg·L-1	1,990.8 ± 317.9	4,317.4 ± 541.1	9,279.1 ± 1,466.3
AUCINF	h*µg·L-1	2,003.8 ± 318.7	4,325.2 ± 541.5	9,292.8 ± 1,468.0
Vz	L	184.5 ± 80.37	197.6 ± 77.76	194.3 ± 72.28
Cl	L·h-1	30.65 ± 4.91	28.18 ± 3.83	26.45 ± 4.34

^aData shown as the mean ± SD.